MX2010008496A - Metodo para la determinacion de sensibilidad a agente anticancerigeno. - Google Patents

Metodo para la determinacion de sensibilidad a agente anticancerigeno.

Info

Publication number
MX2010008496A
MX2010008496A MX2010008496A MX2010008496A MX2010008496A MX 2010008496 A MX2010008496 A MX 2010008496A MX 2010008496 A MX2010008496 A MX 2010008496A MX 2010008496 A MX2010008496 A MX 2010008496A MX 2010008496 A MX2010008496 A MX 2010008496A
Authority
MX
Mexico
Prior art keywords
sensitivity
cancer agent
determination
marker
disclosed
Prior art date
Application number
MX2010008496A
Other languages
English (en)
Inventor
Yusuke Tanigawara
Sayo Suzuki
Shinji Sugimoto
Original Assignee
Univ Keio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Keio filed Critical Univ Keio
Publication of MX2010008496A publication Critical patent/MX2010008496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Electrochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Se proporciona un marcador para determinar sensibilidad a un agente anticancerígeno capaz de distinguir una respuesta terapéutica de un paciente individual, y un medio novedoso para una terapia contra el cáncer utilizando el marcador; el marcador para determinar sensibilidad a un agente anticancerígeno contiene una proteína que une calcio S100A7, 5100A8 o S100A10.
MX2010008496A 2008-01-31 2009-01-30 Metodo para la determinacion de sensibilidad a agente anticancerigeno. MX2010008496A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008021124 2008-01-31
JP2008223384 2008-09-01
PCT/JP2009/000374 WO2009096196A1 (ja) 2008-01-31 2009-01-30 抗がん剤感受性の判定方法

Publications (1)

Publication Number Publication Date
MX2010008496A true MX2010008496A (es) 2010-08-30

Family

ID=40912550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008496A MX2010008496A (es) 2008-01-31 2009-01-30 Metodo para la determinacion de sensibilidad a agente anticancerigeno.

Country Status (13)

Country Link
US (1) US9089540B2 (es)
EP (1) EP2241334A4 (es)
JP (1) JP5461201B2 (es)
KR (1) KR20100130587A (es)
CN (2) CN104784706A (es)
AU (1) AU2009208526A1 (es)
BR (1) BRPI0906573A2 (es)
CA (1) CA2713296A1 (es)
IL (1) IL207169A0 (es)
MX (1) MX2010008496A (es)
NZ (1) NZ586972A (es)
RU (1) RU2010136309A (es)
WO (1) WO2009096196A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495561B1 (en) * 2009-10-30 2016-12-14 Keio University Anticancer agent sensitivity-determining marker
CN102597778B (zh) * 2009-10-30 2016-03-02 学校法人庆应义塾 抗癌剂感受性的判定方法
WO2011052749A1 (ja) 2009-10-30 2011-05-05 学校法人慶應義塾 抗がん剤の感受性の判定方法
WO2012110425A1 (en) * 2011-02-14 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring the response to treatment and for treating colorectal cancer
EP3575799B1 (en) * 2011-03-24 2020-06-24 Keio University Marker for determination of sensitivity to anticancer agent
EP3812009A1 (en) * 2012-02-23 2021-04-28 Keio University Combined anticancer drug sensitivity-determining marker
WO2015119362A1 (ko) * 2014-02-07 2015-08-13 아주대학교산학협력단 Rip3 발현촉진제를 유효성분으로 포함하는 항암보조용 조성물, rip3 발현을 촉진하여 항암제 감수성을 증진시키는 항암 보조제 스크리닝 방법 및 항암제 감수성 모니터링 방법
CN106132435B (zh) 2014-02-07 2021-08-27 亚洲大学校产学协力团 筛选通过促进rip3表达增强抗癌药物的敏感性的抗癌辅剂的方法和试剂盒
JPWO2016031816A1 (ja) * 2014-08-26 2017-06-15 学校法人慶應義塾 抗がん剤の感受性の判定マーカー
WO2016169755A1 (en) 2015-04-21 2016-10-27 Philips Lighting Holding B.V. Lighting-control processor and method for operating a lighting-control processor
KR101834378B1 (ko) * 2015-08-05 2018-03-06 아주대학교산학협력단 Rip3 발현촉진제를 유효성분으로 포함하는 항암보조용 조성물, rip3 발현을 촉진하여 항암제 감수성을 증진시키는 항암 보조제 스크리닝 방법 및 항암제 감수성 모니터링 방법
EP3779451A4 (en) * 2018-03-29 2022-01-12 Keio University MARKER FOR DETERMINING THE SENSITIVITY OF THERAPY WITH AN ANTICANCER AGENT CONTAINING IRINOTECAN
WO2020067228A1 (ja) * 2018-09-28 2020-04-02 学校法人慶應義塾 併用抗がん剤の感受性の判定マーカー
JP7384410B2 (ja) 2020-08-27 2023-11-21 国立大学法人 大分大学 癌治療効果の有効性を予測する方法、予測装置及び予測プログラム

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
EP1604014A4 (en) * 2003-03-20 2008-03-26 Dana Farber Cancer Inst Inc GENE EXPRESSION IN BREAST CANCER
JPWO2005007846A1 (ja) * 2003-04-25 2006-08-31 財団法人癌研究会 腫瘍細胞の抗癌剤に対する感受性を判定する方法
WO2005066371A2 (en) 2003-12-31 2005-07-21 The Penn State Research Foundation Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
GB0412620D0 (en) * 2004-06-05 2004-07-07 Univ Belfast BRCA1 markers
EP1945819B1 (en) * 2005-11-12 2013-03-20 Siemens Healthcare Diagnostics Inc. Gene expression profiles and methods of use
PL2021794T3 (pl) * 2006-05-19 2010-12-31 Hoffmann La Roche Zastosowanie białka S100A 12 jako markera raka okrężnicy i odbytnicy
CN101040843A (zh) 2006-09-22 2007-09-26 济南康泉医药科技有限公司 一种含尼莫司汀及其增效剂的抗实体瘤缓释剂
WO2008073878A2 (en) * 2006-12-11 2008-06-19 Board Of Regents, The University Of Texas System Gene expression profiling of esophageal carcinomas
CN101011351A (zh) 2007-02-12 2007-08-08 济南帅华医药科技有限公司 同载铂类化合物和增效剂的抗癌组合物
EP2140020A2 (en) * 2007-03-15 2010-01-06 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy

Also Published As

Publication number Publication date
EP2241334A4 (en) 2013-06-19
KR20100130587A (ko) 2010-12-13
BRPI0906573A2 (pt) 2015-07-07
IL207169A0 (en) 2010-12-30
CN101932338A (zh) 2010-12-29
RU2010136309A (ru) 2012-03-10
AU2009208526A1 (en) 2009-08-06
JPWO2009096196A1 (ja) 2011-05-26
WO2009096196A1 (ja) 2009-08-06
NZ586972A (en) 2012-03-30
JP5461201B2 (ja) 2014-04-02
CA2713296A1 (en) 2009-08-06
CN104784706A (zh) 2015-07-22
US9089540B2 (en) 2015-07-28
US20100323034A1 (en) 2010-12-23
EP2241334A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
CR20110470A (es) Proteínas de union a il-17
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
IN2014MN02164A (es)
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
WO2012012802A3 (en) Neoepitope detection of disease using protein arrays
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
MX357429B (es) Predictores para el tratamiento del cáncer.
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
NZ609501A (en) Antibodies to notum pectinacetylesterase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal